CN1246020C - Composition for alcohol type fatty liver - Google Patents
Composition for alcohol type fatty liver Download PDFInfo
- Publication number
- CN1246020C CN1246020C CN 03102025 CN03102025A CN1246020C CN 1246020 C CN1246020 C CN 1246020C CN 03102025 CN03102025 CN 03102025 CN 03102025 A CN03102025 A CN 03102025A CN 1246020 C CN1246020 C CN 1246020C
- Authority
- CN
- China
- Prior art keywords
- portions
- dry extract
- chinese medicine
- liver
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 208000010706 fatty liver disease Diseases 0.000 title abstract description 12
- 239000000203 mixture Substances 0.000 title abstract description 4
- 208000004930 Fatty Liver Diseases 0.000 title description 8
- 206010019708 Hepatic steatosis Diseases 0.000 title description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 title description 8
- 239000003814 drug Substances 0.000 claims abstract description 56
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 18
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 abstract description 4
- 206010016262 Fatty liver alcoholic Diseases 0.000 abstract description 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 abstract description 4
- 210000002381 plasma Anatomy 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 210000002700 urine Anatomy 0.000 abstract description 3
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract 2
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 206010036067 polydipsia Diseases 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- -1 metadoxine chemical compound Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 125000003724 cholesterol ester group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses a medicine composition for alcoholic fatty liver, which is composed of, in proportion by weight, 40 to 60 portions of traditional Chinese medicine dry extract and 2 to 5 portions of metadoxine, wherein the traditional Chinese medicine dry extract is prepared from raw materials of the following proportion by weight: 30 to 50 portions of red sage root, 30 to 50 portions of alismatis, 30 to 50 portions of hawthorn and 15 to 25 portions of bupleurum root. The present invention has obvious fat-lowering and liver-protecting action, the activity of acetadehyde dehydrogenase can be increased simultaneously, acetaldehyde and ethanol in blood plasma and urine are rapidly removed, and liver cirrhosis can be effectively controlled and eliminated because of longtime excessive drinking.
Description
Technical field
The present invention relates to pharmaceutical product, specifically be used for the pharmaceutical composition of alcohol fatty hepatopathy.
Technical background
Alcoholic fatty liver is the cercinoma prophase pathologic change of alcoholic liver diseases such as alcoholic hepatitis, alcoholic fibrosis, alcoholic cirrhosis.Alcoholic liver disease has become one of between twenty and fifty main causes of death of developed country.Also raising year by year, it is reported to suffer from fatty liver to some extent in China's pathogenesis of fatty liver rate at the population of China nearly 10%, and obesity be addicted to drink and the crowd of diabetes in more up to 50～60%.Wherein hepatic fibrosis takes place in 25% patient, and 1.5%-8% patient develops into liver cirrhosis.Therefore, how to reverse fatty liver, reduce the incidence rate of alcoholic hepatitis, alcoholic cirrhosis, caused countries in the world medical expert's great attention.The medicine of research and development treatment alcoholic liver disease is the emphasis and the difficult point of current global the world of medicine.
At present, be used to prevent and the medicine for the treatment of fatty liver has manyly, for example the blood fat reducing medicine includes clofibrate, nicotinic acid class, choline medicine; Hepatoprotective degrease medicine includes unsaturated fatty acid and phospholipid, S-ademetionine, ursodesoxycholic acid etc.But all there are some serious weak points in these medicines.Can order about blood fat as many fat-reducing medicaments and more concentrate on liver metabolism, promote fat in liver, to accumulate on the contrary, and the infringement liver function; And hepatoprotective degrease medicine need be taken usually for a long time, and expensive expenses for medicine makes the patient be difficult to bear.In addition, the phenomenon of transaminase's knock-on also can appear in some hepatoprotective degrease medicine when drug withdrawal suddenly.The infringement that liver is caused for fear of insobriety, present commercially available many antialcoholic drugs that have, but the general solution yeast for brewing rice wine can only be to accelerate ethanol removing in vivo to relieve the effect of alcohol usually, and the alcoholic fatty liver therapeutical effect that causes drinking for a long time is very little, as the metadoxine that uses clinically, be under the situation of using therapeutic dose, have the effect that good quickening ethanol decomposes, removes, but a little less than the effect of its blood fat reducing and anti-hepatic fibrosis.Moreover this medicine costs an arm and a leg, and taking dose is big.So its extensive use also is restricted.
Summary of the invention
Purpose of the present invention just provides a kind of determined curative effect, cheap, the pharmaceutical composition that is used for the treatment of alcoholic fatty liver that toxic and side effects is little.
The object of the present invention is achieved like this: be used for the pharmaceutical composition of alcohol fatty hepatopathy, be made up of the component of following weight proportion: Chinese medicine dry extract 40-60 part, metadoxine 2-5 part; Wherein said Chinese medicine dry extract is to be made by following materials of weight proportions medicine: Radix Salviae Miltiorrhizae 30-50 part, Rhizoma Alismatis 30-50 part, Fructus Crataegi 30-50 part, Radix Bupleuri 15-25 part.
The preferred weight proportioning of its each crude drug of Chinese medicine dry extract among the present invention is: Radix Salviae Miltiorrhizae 35-45 part, Rhizoma Alismatis 40-50 part, Fructus Crataegi 40-50 part, Radix Bupleuri 20-25 part.
The Chinese medicine dry extract among the present invention and the preferred weight proportioning of metadoxine are 45-50 part: 4-5 part.
The present invention can be prepared into the various dosage forms of preparing and taking of being suitable for such as capsule, tablet, oral liquid.
The preparation method that the present invention is prepared into capsule is:
At first prepare the Chinese medicine dry extract:
Take by weighing each raw material of Chinese medicine medicine, after the mixing, soaked 24 hours, decoct twice, each 1 hour, merging filtrate added 60% ethanol precipitation, reclaimed ethanol, was concentrated into driedly, was ground into fine powder and was the Chinese medicine dry extract.
Take by weighing the Chinese medicine dry extract, add commercially available metadoxine, mix homogeneously, encapsulated, every intragranular contains medicine 0.5 gram of the present invention.
The usage of capsule of the present invention, consumption are: for oral administration, every day the 4-8 grain, every capsules 0.5 gram.Generally took 2--4 month, and can receive notable therapeutic effect.
The part of innovation of the present invention is selectively the different mutual compatibilities of raw material of Chinese medicine medicine, and adds the metadoxine chemical compound, makes it have good synergism.
Medicine of the present invention has tangible blood fat reducing, hepatoprotective effect in the application of treatment ethanol fatty liver, can increase the activity of aldehyde dehydrogenase simultaneously, accelerates acetaldehyde, alcoholic acid removing in blood plasma and the urine; Can effectively control and eliminate the fatty liver that causes because of long-term insobriety.
Chinese medicine dry extract in the medicine of the present invention, but selected Radix Salviae Miltiorrhizae triglyceride reducing promote the oxidation of fat in liver, and blood vessel dilating is arranged, improve liver blood circulation, increase the effect of liver blood flow amount, also can promote liver cell regeneration simultaneously, and have the effect of certain fibrosis; Rhizoma Alismatis has preventive effect to hepatic injury, and its contained triterpenoid compound can reduce the generation of synthetic cholesterol S-acetyl-coenzyme-A; Contained organic acid and flavone in the Fructus Crataegi has blood fat reducing and reduces cholesterol and the deposition of cholesterol ester in arterial wall; But the Radix Bupleuri triglyceride reducing quickens cholesterol-C
14And the drainage of metabolite.
Above-mentioned raw material of Chinese medicine medicine all has certain fat-reducing liver-protecting effect though its single is used, and its effect is slow and render a service faint.Pharmaceutical composition of the present invention is with the mutual compatibility of each medicine material medicine, and adding metadoxine chemical compound, makes to have produced good synergism between each crude drug, has obtained good curative effect.
Chinese medicine dry extract in the medicine of the present invention, also can add in its Chinese medicine crude drug Herba Artemisiae Scopariae, Pericarpium Citri Reticulatae etc. have protect the liver, the Chinese herbal medicine of spleen invigorating effect, it can obtain excellent curative equally.
Beneficial effect of the present invention has obtained confirmation by clinical experiment.
The experiment case selection: 70 routine Patients with Fatty Liver through B ultrasonic and CT make a definite diagnosis, be the male, long-term history of drinking history is arranged, age 29-70 year, the course of disease year did not wait from half a year to 12.70 routine patients are divided into two groups at random, i.e. experimental group and matched group.Medication three months.Experimental group: take medicine capsule of the present invention, every day secondary, each 2-4 grain, every capsules 0.5g, (it includes metadoxine 40mg), matched group therapeutic dose is routinely taken metadoxine sheet (production of Linzi, Shandong pharmaceutical factory), that is: every day 1000mg, divide secondary to take.
Experimental result sees Table 1, table 2.
Table 1: hemorheology change before and after the treatment (x ± S)
| Matched group | The treatment group | P | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| The low viscosity of cutting of whole blood | 10.31±1.25△ | 9.48±1.35 | 10.32±1.27 | 8.87±1.30 | ＜0.01 |
| The whole blood height is cut viscosity | 7.30±0.42△ | 7.12±0.57 | 7.28±0.56 | 6.12±0.36 | ＜0.01 |
| Packed cell volume | 0.048±0.042△ | 0.47±0.56 | 0.48±0.026 | 0.44±0.031 | ＜0.01 |
| Fibrinogen (g/L) | 4.77±0.84△ | 4.66±0.76 | 4.78±0.97 | 3.64±0.65 | ＜0.01 |
| Plasma viscosity | 1.85±0.08△ | 1.80±0.07 | 1.87±0.12 | 1.66±0.07 | ＜0.01 |
Table 2: blood fat change before and after the treatment (x ± S)
| Matched group | The treatment group | P | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Triglyceride (mmol/L) | 2.88±1.05△ | 1.76±0.59 | 2.88±1.07 | 1.60±0.52 | ＜0.01 |
| Cholesterol (mmol/L) | 6.07±1.01△ | 5.42±0.76 | 6.05±1.05 | 4.62±0.51 | ＜0.01 |
| Low-density lipoprotein (mmol/L) | 4.98±0.76△ | 3.86±0.72 | 4.95±0.88 | 3.50±0.56 | ＜0.01 |
| High-density lipoprotein (mmol/L) | 1.14±0.20△ | 1.30±0.46 | 1.13±0.22 | 1.40±0.52 | ＜0.01 |
| ApoA 1 (g/L) | 1.29±0.14△ | 1.29±0.24 | 1.29±0.17 | 1.26±0.12 | ＜0.01 |
| Apolipoprotein B 1 (g/L) | 1.23±0.21△ | 0.98±0.56 | 1.23±0.21 | 0.92±0.15 | ＜0.01 |
Experiment shows, before treatment, experimental group and matched group multinomial clinical assay index P＞0.5 of comparing, illustrate that two groups of cases have comparability.After the treatment, the various clinical assay indexs of experimental group all are better than matched group, statistical procedures P＜0.01 only, illustrate that medicine of the present invention is including under the situation that Mei Duotaxin is significantly less than its therapeutic dose, its blood fat reducing, anti-fibrosis effect have been obtained the therapeutic effect that significantly is better than Mei Duotaxin normal therapeutic amount.
The experiment of relieving the effect of alcohol contrasts
Select the patient of 50 routine insobriety, be divided into two groups at random, i.e. experimental group and matched group.Experimental group: take medicine capsule of the present invention, 4 of decoction being taken at a draught, every capsules 0.5g, (it includes metadoxine 40mg), matched group therapeutic dose is routinely taken the metadoxine sheet, decoction being taken at a draught 1000mg.
Experiment shows: two groups in accelerating blood plasma and urine aspect acetaldehyde, the alcoholic acid scavenging action, no significant difference.Illustrate also that thus medicine of the present invention is including under the low dosage Mei Duotaxin situation, has obtained the effect of relieving the effect of alcohol of Mei Duotaxin normal dose.
The specific embodiment
Embodiment 1
Preparation Chinese medicine dry extract: take by weighing Radix Salviae Miltiorrhizae 45kg, Rhizoma Alismatis 30kg, Fructus Crataegi 50kg, Radix Bupleuri 25kg soaked 24 hours, decocted twice, and each 1 hour, merging filtrate added 60% ethanol precipitation, and recovery ethanol is concentrated into driedly, is ground into dry extract.
Take by weighing dry extract 46kg, add commercially available metadoxine 4kg, mix homogeneously, encapsulated, every intragranular contains medicated powder 0.5 gram.
Following examples 2-5, its preparation method are with embodiment 1, and just the selection and the proportioning of each crude drug are different, but all can obtain effect of the present invention.
Chinese medicine dry extract among the embodiment 2-5:
Embodiment 2 gets embodiment 2 described dry extract 50kg in the above-mentioned table, adds metadoxine 4kg.
Embodiment 3 gets the dry extract 45kg described in the embodiment 3 in the above-mentioned table, adds metadoxine 5kg.
Embodiment 4 gets the dry extract 60kg described in the embodiment 4 in the above-mentioned table, adds metadoxine 2kg.
Embodiment 5 gets the dry extract 40kg described in the embodiment 5 in the above-mentioned table, adds metadoxine 3kg.
Claims (3)
1, a kind of pharmaceutical composition that is used for the alcohol fatty hepatopathy is characterized in that it is made up of the component of following weight proportion: Chinese medicine dry extract 40-60 part, metadoxine 2-5 part; Wherein said Chinese medicine dry extract is to be made by following materials of weight proportions medicine: Radix Salviae Miltiorrhizae 30-50 part, Rhizoma Alismatis 30-50 part, Fructus Crataegi 30-50 part, Radix Bupleuri 15-25 part.
2, the pharmaceutical composition that is used for the alcohol fatty hepatopathy according to claim 1 is characterized in that the weight proportion of said its each crude drug of Chinese medicine dry extract is: Radix Salviae Miltiorrhizae 35-45 part, Rhizoma Alismatis 40-50 part, Fructus Crataegi 40-50 part, Radix Bupleuri 20-25 part.
3, the pharmaceutical composition that is used for the alcohol fatty hepatopathy according to claim 1, the weight proportion that it is characterized in that said Chinese medicine dry extract and metadoxine is 45-50 part: 4-5 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03102025 CN1246020C (en) | 2003-01-28 | 2003-01-28 | Composition for alcohol type fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03102025 CN1246020C (en) | 2003-01-28 | 2003-01-28 | Composition for alcohol type fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1520833A CN1520833A (en) | 2004-08-18 |
| CN1246020C true CN1246020C (en) | 2006-03-22 |
Family
ID=34281554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03102025 Expired - Fee Related CN1246020C (en) | 2003-01-28 | 2003-01-28 | Composition for alcohol type fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1246020C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822786A (en) * | 2017-03-01 | 2017-06-13 | 潘鑫 | Treat the Chinese herbal granules of non-alcoholic fatty liver disease |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100877600B1 (en) * | 2006-11-30 | 2009-01-08 | 재단법인서울대학교산학협력재단 | Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis |
| CN104547911A (en) * | 2014-12-30 | 2015-04-29 | 朱惊涛 | Traditional Chinese medicine preparation for treating liver-stomach disharmony type alcoholic liver disease and preparation method |
-
2003
- 2003-01-28 CN CN 03102025 patent/CN1246020C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822786A (en) * | 2017-03-01 | 2017-06-13 | 潘鑫 | Treat the Chinese herbal granules of non-alcoholic fatty liver disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1520833A (en) | 2004-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102370686B (en) | Medicinal composition for treating chronic liver disease and application thereof | |
| CN1246020C (en) | Composition for alcohol type fatty liver | |
| CN1052164C (en) | Traditional Chinese medicine preparation for treating senile dementia | |
| CN1686294A (en) | Medicinal composition for treating coronary heart disease stenocardia | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN112656802B (en) | Application of pulsatilla saponin B4 in preparation of medicine for treating multiple sclerosis | |
| CN1730090A (en) | Chinese traditional medicinal composition for treating hepatitis and process for preparing the same | |
| CN1682837A (en) | Medicine for regulating blood fat and its preparing method | |
| CN100336540C (en) | Medicine composition for treating hyperlipemia and its prepn | |
| CN1159029C (en) | Blood lipoid regulating medicine and its prepn | |
| CN1843460A (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN1456309A (en) | Antilipemic antiatherosclerosis medicine composition and preparing method, application thereof | |
| CN1386499A (en) | Application of diphenylvinyl phenol glucosides in preparing hypolipemic medicine | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process | |
| CN1047944C (en) | Capsule for curing hepatitis | |
| CN1054524C (en) | Medicine composition for treating diabetes mellitus | |
| CN108813564A (en) | There are the composition and health food of defencive function to chemical damage | |
| CN115554345B (en) | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method | |
| CN101850031A (en) | Pueraria isoflavone capsule | |
| CN1054525C (en) | Medicinal composition for treating diabetes involving lower jiao | |
| CN1943658A (en) | A Chinese traditional medicinal composition for treating acute, chronic hepatitis and preparing method | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN1476882A (en) | Medicine with function of reducing blood sugar and its preparation method | |
| CN100340267C (en) | Chinese medicinal preparation for treating fattly liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEBEI MEDICAL UNIVERSITY Free format text: FORMER OWNER: WANG SHUYUE Effective date: 20060414 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060414 Address after: 050017 Hebei Medical University, 361 East Zhongshan Road, Hebei, Shijiazhuang Patentee after: Hebei Medical University Address before: 050017 School of pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, Hebei Patentee before: Wang Shuyue |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |